Alzheimer's disease

[Functional Neuromodulation Ltd. (PR Newswire, LLC)] Functional Neuromodulation Ltd. announced that it has received Breakthrough Device designation from the Center for Devices and Radiological Health of the FDA for the Vercise™ Deep Brain Stimulation Systems, developed and manufactured by Boston Scientific Corporation, in the treatment of patients 65 years and older with mild probable Alzheimer's disease.

[Athira Pharma, Inc.] Athira Pharma, Inc. announced that patient dosing has begun in ACT-AD, a Phase II randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer's disease. ATH-1017 is a small molecule therapeutic designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in the central nervous system, in order to promote brain health and function.

[Neuropharmacology] The authors review the pathophysiology of Alzheimer's disease and highlight the sigma ligands that display the capability of preventing or even reversing amyloid-β (Aβ) - and amyloid-β oligomers (AβOs) -induced neurotoxicity and blocking the signal transduction caused by AβOs.

[Neurotrope, Inc. (PR Newswire LLC)] Neurotrope, Inc.announced dosing of the first patient in its ongoing, long-term Phase II study of Bryostatin-1 for the treatment of Alzheimer's disease. The study was conducted in collaboration with the National Institutes of Health under a $2.7 million grant to Neurotrope.

[European Journal of Neuroscience] The authors describe how glial cells play a role in adult hippocampal neurogenesis in both health and disease, especially focusing on glia‐derived factors.

[Glia] Two‐photon vital microscopy demonstrated normal morphology and resting motility of microglia but strongly diminished number of microglial cells that migrated to the photolesion site in 5xFAD mice.